Search - tctmd.com

Displaying 181 - 190 of 190

Sort: Relevancy | Date

News Daily News

FDA 与阿玛琳之间的和解是否会减弱该局对标签外用途推广的监督？

Michael O'Riordan

March 09, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol

February 04, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2016

Shelley Wood

February 01, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Industry News

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

January 21, 2016

News Conference News AHA 2015

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

Shelley Wood

November 05, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Daily News

Zero Calcium Score Provides 15-Year Mortality ‘Warranty’ for Asymptomatic Patients

August 06, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

Presentation TCT 2014

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

Presenter: Ori Ben-Yehuda, Harvey D. White, Roxana Mehran, Evan A. Stein

September 15, 2014

Advertisement

FDA 与阿玛琳之间的和解是否会减弱该局对标签外用途推广的监督？

Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol

TCTMD’s Top 10 Most Popular Stories for January 2016

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Zero Calcium Score Provides 15-Year Mortality ‘Warranty’ for Asymptomatic Patients

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content